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Abstract
Background: The hyperosmolar hyperglycemic state (HHS) is a dangerous complication that can arise with diabetes 
mellitus. Emergent treatment is necessary to reinstate hemodynamic stability, as mortality rates for HHS are exceptionally high 
and can have multiple complications.  
Case Report: A 42-year-old female presented unresponsive to the emergency department. Upon arrival, the patient’s 
examination was consistent with hypovolemia and tachycardia.  Review of systems included a one-week history of nausea and 
vomiting. The patient had stopped all of her medications one year prior, only restarting metformin one week prior to admission. 
Her presenting systolic blood pressure was 119 mmHg before she developed respiratory failure secondary to a poor mental state. 
The presenting blood sugar level was 1263 mg/dL, and ketones were not detected in her urine. The patient recovered from her 
HHS and was discharged in a stable condition. 
Conclusion: This case study postulates that the patient’s excessive nausea and vomiting led to pancreatitis secondary to 
ischemia, which induced a HHS. This is important because hyperglycemia superimposed on any ischemic insult can increase the 
risk of multiorgan failure, as with our patient.  Thus, recognition and management of resulting complications needs to be emergent.
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Introduction
The hyperosmolar hyperglycemic state (HHS) is one of 
the worst complications that can arise with diabetes mellitus; 
it is characterized by extreme hyperglycemia, increased 
serum osmolality, and prolonged dehydration in the absence 
of ketoacidosis [1]. In this situation, emergent treatment is 
necessary to reinstate hemodynamic stability. The mortality 
rate for HHS is exceptionally high and can have multiple side 
effects. According to Chen et al. [2], a hospital-based analysis 
illustrated a case fatality rate for HHS of 18.83% over the 
course of 28 days.
This case illustrates the various complications that 
can arise from HHS, emphasizing the necessity for careful 
monitoring during the inpatient stay.  The initiating event in 
HHS is glucosuric diuresis, which leads to free water loss and 
intravascular hyperosmolarity, this can exacerbate or cause 
acute kidney injury due to dehydration [3,4].  Traditionally 
HHS and diabetic ketoacidosis have been described as two 
separate states, but one-third of the patients have symptoms 
from both conditions [5]. While our case illustrates HHS 
arising from ischemic pancreatitis, other precipitating 
factors can include infections, medications, non-compliance, 
undiagnosed diabetes, substance abuse and other coexisting 
diseases [3].  Infections such as pneumonia, gastroenteritis, 
and urinary tract infections can also be a common cause. 
Case Description
A 42-year-old unresponsive Caucasian female with a 
BMI of 35.0 was transferred to our facility with altered mental 
status and elevated blood glucose levels.  She had experienced 
a one-week history of flu-like symptoms as well as nausea and 
hematemesis. Moreover, she had not taken insulin for over one 
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year and had stopped her metformin for a month. She restarted 
her metformin a few days prior to this episode, which may have 
induced her nausea and vomiting. Upon arrival to our facility, 
her blood glucose level was reported to be 1263 mg/dL. Her 
past medical history was relevant for type II diabetes mellitus, 
chronic back pain, hypothyroidism, hypertriglyceridemia, 
bipolar disorder, asthma and tobacco use. 
Her initial laboratory values obtained from our hospital 
were as follows: her white blood cell count was 19.24x103 
cells/mm3, hemoglobin was 15.2 g/dL, sodium was 160 
mEq/L, potassium was 3.9 mEq/L, chloride was 122 mEq/L, 
bicarbonate was 15 mEq/L, BUN - 60 mg/dL, creatinine - 2.4 
mg/dL, glucose was rechecked and was 723mg/dL, creatine 
kinase of 1039U/L, amylase of 980 U/L, lipase of 9992U/L, 
and triglycerides were 646 mg/dL. She had an anion gap of 
23. Her arterial blood gas resulted in a pH of 7.30, a pCO2 
of 36, a pO2 of 76 and bicarbonate of 17. Due to her elevated 
lipase and a CT scan suggestive of pancreatitis, the cause of 
her HHS was likely due to volume depletion, which led to 
ischemic pancreatitis. 
The initial management was aggressive fluid resuscitation 
along with boluses of normal saline and an insulin drip. She 
was then admitted to the intensive care unit because her blood 
pressure had dropped to 91/54 mmHg and her respiratory rate 
escalated to 42, requiring intubation and vasopressors.  A 
week into her hospitalization, her blood culture was positive 
for staphylococcus, with symptoms of systemic inflammatory 
response syndrome. The patient recovered from her HHS and 
her other various coexisting illnesses and was discharged in a 
stable condition.
Discussion
This was an unusual case of HHS, caused by ischemic 
pancreatitis, secondary to her metformin-induced nausea and 
vomiting, although her concomitant positive blood culture 
could have aggravated her state, as infections are predisposing 
factors for HHS [6]. However, because she suffered from 
subsequent distributive shock and was hypotensive requiring 
pressors, this could have also exacerbated her condition. 
It is well documented in the literature that metformin 
can cause a rare and potentially fatal side effect, lactic 
acidosis. However, a more recent Cochrane review of 347 
articles (2010) showed that there was no evidence based on 
prospective comparative trials or observational cohort studies 
that metformin increased the risk for lactic acidosis compared 
to any other antihyperglycemic medications [7].  In the 70,490 
patient-years of the pooled metformin group, there were no 
cases of fatal or non-fatal lactic acidosis found [7].  Moreover, 
according to Chan et al. [8], the low prevalence of metformin-
associated lactic acidosis was comparable to the prevalence 
of sulfonylurea-induced hypoglycemia; metformin had many 
benefits for management of type II diabetes mellitus, assuming 
that recommended guidelines for metformin use were adhered 
to [8]. Lalau et al. [9] also performed a literature search on 
the link between metformin and lactic acidosis in metformin 
therapy; and there was no true metformin-associated lactic 
acidosis and no mortalities due to metformin alone were 
found.  Thus, it was ruled out that this patient’s acidosis and 
HHS were caused by or induced by the use of metformin.
Sepsis and shock are serious manifestations of HHS, for 
if the patient develops these, prompt and proper treatment is 
needed as they have a high mortality rate, especially if the 
patient has various risk factors such as bacteremia, age greater 
than 65 years, immunosuppression, community acquired 
pneumonia, and genetic factors [10].  Fluid therapy needs to 
be administered as soon as possible, and because this patient 
was also suffering from ischemic pancreatitis, these two 
situations likely exacerbated one another; therefore, the need 
for intravascular repletion with fluids was even more vital [10]. 
Our patient experienced distributive shock as a consequence 
of her ischemic state, further leading to her multiorgan failure.
This case was an important review, as HHS is a life-
threatening condition which needs to be treated immediately. 
HHS can be easily overlooked; thus, this discussion becomes 
important when assessing how to properly and quickly 
treat these patients. There are many factors that can cause 
or provoke this condition.  Moreover, it is uncommon for 
ischemic pancreatitis to be a source of HHS, which adds to 
the complexity of this case study. Some of the salient features 
of this case report include the questionable and irregular 
onset of HHS, its cause by ischemic pancreatitis, and other 
contributing factors, namely, sepsis concurrent with her recent 
restarting of metformin.  Usually, the intake of metformin 
would lead to a side effect of lactic acidosis, which would 
induce diabetic ketoacidosis; however, in this case it may have 
led to HHS. Finally, this patient developed sepsis throughout 
her hospitalization while suffering from HHS. Both sepsis and 
HHS are conditions which can lead to immediate mortality, 
and when they occur simultaneously, critical and attentive 
care is vital for the patient. Mortality rates for both HHS and 
DKA are exceptionally high, and any additional condition 
can exacerbate the already severe situation. It is important to 
always monitor the HHS patients, as infections of any kind 
can increase mortality through these mechanisms.  HHS is 
a state which has a high mortality if not monitored properly, 
and can worsen if any comorbidities exist, such as sepsis or 
ischemic pancreatitis.
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